Volta Finance Limited reported NAV of €256.0 million as at 31 January 2026, alongside annualised cashflow generation of around 16% and a share price total return of 1.8% over the..
Gene therapy is gaining investor attention because it offers a more direct way to treat rare genetic diseases, while also bringing important questions around access, cost and long-term evidence...
Interim results for the six months to 28 February 2026 show Baillie Gifford Japan Trust delivered positive NAV and share price returns, but lagged the benchmark, while continuing share buybacks..
The Merchants Trust said NAV total return was 18.9% for the year ended 31 January 2026 and proposed a total dividend of 29.5p, marking its 44th consecutive annual increase...
Atalaya Mining has acquired 4.5 million Lara Exploration shares through a private placement for C$13.5 million, giving it an approximate 7.3% stake. Lara plans to use the proceeds to advance..
Ahead of full-year results on 28 May 2026, SSE said it expects adjusted EPS of 147–152 pence for the year ended 31 March 2026. The company also reported a sharp..
Smiths has completed its acquisition of DRC Heat Transfer, adding complementary thermal products and solutions to Flex-Tek and strengthening its position in growing markets such as backup power and mission-critical..
In the Phase III EMERALD-3 trial, AstraZeneca’s Imfinzi- and Imjudo-based regimen plus lenvatinib and TACE significantly improved progression-free survival versus TACE alone in embolisation-eligible unresectable hepatocellular carcinoma, with an interim..
Firering Strategic Minerals said production at its Limeco lime project in Zambia continues to improve, with Kiln 2 now averaging more than 70 tonnes per day during its optimisation phase...
Cizzle Biotechnology has entered into a new unsecured convertible loan note facility with existing investor Frazer Lang, giving the company access to up to £250,000 to support the planned commercial..
Hardman & Co highlights that Arbuthnot Banking Group delivered strong growth in deposits, funds under management and specialist lending in 2025, despite a 31% fall in pre-tax profit driven by..
Helium may look like a niche material, but its role in MRI machines and rocket systems gives it real strategic value when supply comes under pressure...
Hardman & Co analyst Mark Thomas outlines ICG Enterprise Trust’s strong 2025 performance, disciplined capital allocation, and long-term strategy focused on delivering private equity returns with reduced risk and enhanced..
Verge Technologies President and Chief Executive Officer Jimmy Jobe discusses the growing operational, cost and performance challenges of multi-cloud environments and explains how SentientDB is designed to unify database management..
Gattaca CEO Matthew Wragg outlines the group’s first-half performance, highlights growth across key markets, reviews the InfoSec People acquisition, and explains why the business believes it offers a focused long-term..
European equities rebounded strongly as de-escalation hopes and firmer manufacturing data pushed investors back towards airlines, banks and other cyclical sectors...
Executive Director Dr Dan Gooding discusses Nuformix’s NXP002 programme for idiopathic pulmonary fibrosis, the value of FDA orphan drug designation, and how the recent fundraise supports partnering discussions...
Chinese equities opened April with renewed strength as improving external sentiment and a surge in buyback activity gave investors a more confident near-term outlook...
Volta Finance Limited reported NAV of €256.0 million as at 31 January 2026, alongside annualised cashflow generation of around 16% and a share price total return of 1.8% over the period...
Gene therapy is gaining investor attention because it offers a more direct way to treat rare genetic diseases, while also bringing important questions around access, cost and long-term evidence...
Interim results for the six months to 28 February 2026 show Baillie Gifford Japan Trust delivered positive NAV and share price returns, but lagged the benchmark, while continuing share buybacks and adding new growth holdings...
The Merchants Trust said NAV total return was 18.9% for the year ended 31 January 2026 and proposed a total dividend of 29.5p, marking its 44th consecutive annual increase...
Atalaya Mining has acquired 4.5 million Lara Exploration shares through a private placement for C$13.5 million, giving it an approximate 7.3% stake. Lara plans to use the proceeds to advance the Planalto copper-gold project in Brazil and for general corporate purposes...
Ahead of full-year results on 28 May 2026, SSE said it expects adjusted EPS of 147–152 pence for the year ended 31 March 2026. The company also reported a sharp rise in networks investment, renewables output of around 14.5 TWh and capital investment of about £3.5bn...
Smiths has completed its acquisition of DRC Heat Transfer, adding complementary thermal products and solutions to Flex-Tek and strengthening its position in growing markets such as backup power and mission-critical applications...
In the Phase III EMERALD-3 trial, AstraZeneca’s Imfinzi- and Imjudo-based regimen plus lenvatinib and TACE significantly improved progression-free survival versus TACE alone in embolisation-eligible unresectable hepatocellular carcinoma, with an interim trend toward overall survival benefit...
Firering Strategic Minerals said production at its Limeco lime project in Zambia continues to improve, with Kiln 2 now averaging more than 70 tonnes per day during its optimisation phase...
Cizzle Biotechnology has entered into a new unsecured convertible loan note facility with existing investor Frazer Lang, giving the company access to up to £250,000 to support the planned commercial launch of its CIZ1B biomarker test in North America, expansion in the UK and Europe, and ongoing clinical work with Moffitt Cancer Center...
Hardman & Co highlights that Arbuthnot Banking Group delivered strong growth in deposits, funds under management and specialist lending in 2025, despite a 31% fall in pre-tax profit driven by lower margins and softer one-off activity. The group remains well capitalised, conservatively managed and priced at a steep discount to book value...
Helium may look like a niche material, but its role in MRI machines and rocket systems gives it real strategic value when supply comes under pressure...
Hardman & Co analyst Mark Thomas outlines ICG Enterprise Trust’s strong 2025 performance, disciplined capital allocation, and long-term strategy focused on delivering private equity returns with reduced risk and enhanced liquidity...
Verge Technologies President and Chief Executive Officer Jimmy Jobe discusses the growing operational, cost and performance challenges of multi-cloud environments and explains how SentientDB is designed to unify database management through AI-driven automation...
Gattaca CEO Matthew Wragg outlines the group’s first-half performance, highlights growth across key markets, reviews the InfoSec People acquisition, and explains why the business believes it offers a focused long-term investment case...
European equities rebounded strongly as de-escalation hopes and firmer manufacturing data pushed investors back towards airlines, banks and other cyclical sectors...
Executive Director Dr Dan Gooding discusses Nuformix’s NXP002 programme for idiopathic pulmonary fibrosis, the value of FDA orphan drug designation, and how the recent fundraise supports partnering discussions...
Chinese equities opened April with renewed strength as improving external sentiment and a surge in buyback activity gave investors a more confident near-term outlook...
